GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Checkpoint Therapeutics Inc (NAS:CKPT) » Definitions » Price-to-Free-Cash-Flow

Checkpoint Therapeutics (Checkpoint Therapeutics) Price-to-Free-Cash-Flow : N/A (As of Jun. 02, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Checkpoint Therapeutics Price-to-Free-Cash-Flow?

As of today (2024-06-02), Checkpoint Therapeutics's share price is $1.90. Checkpoint Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.95. Hence, Checkpoint Therapeutics's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Checkpoint Therapeutics's Price-to-Free-Cash-Flow or its related term are showing as below:

CKPT's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 30.975
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Checkpoint Therapeutics's Free Cash Flow per Share for the three months ended in Mar. 2024 was $-0.20. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-1.95.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 5.00% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 15.70% per year.

During the past 9 years, Checkpoint Therapeutics's highest 3-Year average Free Cash Flow per Share Growth Rate was 27.40% per year. The lowest was -82.50% per year. And the median was 2.60% per year.


Checkpoint Therapeutics Price-to-Free-Cash-Flow Historical Data

The historical data trend for Checkpoint Therapeutics's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Checkpoint Therapeutics Price-to-Free-Cash-Flow Chart

Checkpoint Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only - - - - -

Checkpoint Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Checkpoint Therapeutics's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Checkpoint Therapeutics's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Checkpoint Therapeutics's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Checkpoint Therapeutics's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Checkpoint Therapeutics's Price-to-Free-Cash-Flow falls into.



Checkpoint Therapeutics Price-to-Free-Cash-Flow Calculation

Checkpoint Therapeutics's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=1.90/-1.947
=N/A

Checkpoint Therapeutics's Share Price of today is $1.90.
Checkpoint Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.95.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Checkpoint Therapeutics  (NAS:CKPT) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Checkpoint Therapeutics Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Checkpoint Therapeutics's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Checkpoint Therapeutics (Checkpoint Therapeutics) Business Description

Traded in Other Exchanges
Address
95 Sawyer Road, Suite 110, Waltham, MA, USA, 02453
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in us. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). It emphasizes developing novel immuno-oncology and checkpoint inhibitor antibodies as well as oral targeted anti-cancer therapies consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP).
Executives
William Garrett Gray officer: See Remarks 2 GANSEVOORT STREET,, 9TH FLOOR, NEW YORK NY 10014
Oliviero James F Iii director, officer: CEO, President and Director C/O KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON AVENUE, NEW YORK NY 10022
Fortress Biotech, Inc. 10 percent owner 1111 KANE CONCOURSE, SUITE 301, BAY HARBOR ISLANDS FL 33154
Michael S Weiss director 750 LEXINGTON AVE, NEW YORK NY 10022
Neil Herskowitz director 2109 BROADWAY, SUITE 206, NEW YORK NY 10023
Christian Bechon director C/O LFB, 3, AVENUE DES TROPIQUES, LES ULIS, COURTABOEUF I0 91940
Barry M Salzman director 464 COMMON STREET, SUITE 301, BELMONT MA 02478
Scott Boilen director 2 SKYLINE DRIVE, HAWTHORNE NY 10532
Rosenwald Lindsay A Md director 375 PARK AVE, NEW YORK NY 10152
David J Horin officer: Interim CFO 1270 AVENUE OF THE AMERICAS, 16TH FLOOR, NEW YORK NY 10020

Checkpoint Therapeutics (Checkpoint Therapeutics) Headlines

From GuruFocus